N/A N=14 Impact Loading Effect on Bone Biomarkers in Female Runners
Relative Energy Deficiency in Sport
Primary: Change in Bone Remodeling Biomarker - N-terminal Propeptide of Type 1 Procollagen — -3.1; 1.1 ng/mL — p=0.246
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=46 Predicting Peanut Anaphylaxis and Reducing Epinephrine
Anaphylaxis Food
Primary: Anaphylaxis Occurrence Rates in Each Group — 9; 10 Participants — p=0.77
N/A N=122 Using a Mirror in the Second Stage of Labor: Effects on Duration and Birth Experience
Labor Stage, Second
Primary: Childbirth Experience Questionnaire (CEQ) Total Score — 73.85; 70.22 units on a scale
Phase 2 N=30 Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder
Temporomandibular Disorder
Primary: Brief Pain Inventory (BPI) Pain Severity at 20 Weeks — 1.72; 1.42 score on a scale — p=0.567
Phase 2 N=68 Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Myeloid Leukemia, Chronic · Acute Myelogenous Leukemia · Myelodysplastic Syndromes (MDS)
Primary: GvHD Free Relapse Free Survival (GRFS) — 1; 1; 0; 9 Participants
N/A N=3,011 A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.
COVID-19
Primary: Number of Participants Classified Based on Education
N/A N=65 MMG vs. EMG for Cortical Breach Detection
Low Back Disorder
Primary: Success of Pedicle Screw Trajectories — 296; 5; 2 Screws
N/A N=92 A Prospective, Randomized, Controlled Multi-center Study of ArtiFascia® Dural Repair Patch Compared With Commercially Available Dural Substitutes. To Evaluate the Safety and Effectiveness of ArtiFascia® in Subjects Requiring Dural Repair.
Dural Tear · Cerebrospinal Fluid Leak
Primary: Absence of Cerebrospinal Fluid Fistula (Drainage From Wound or Sinus) and Pseudo-meningocele Within 6 Months Post-operative as Evaluated by MRI Imaging. — 0; 0; 27; 58…
N/A N=820 TYRO Couples Project Study
Couples
Primary: Primary Outcome Measure 1: Employment Attitudes — 4.16; 4.13 score on subscale
N/A N=67 The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss
Myeloma · Monoclonal Gammopathy of Undetermined Significance (MGUS) · Smouldering Myeloma
Primary: Primary Outcome 1: Quantifying Tumour Burden [Correlations With Apparent Diffusion Coefficient (ADC) Measurements] — -0.66; NA; -0.28; 0.48 Pearson's correlation…
Phase 3 N=478 Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis
Postmenopausal Women With Osteoporosis
Primary: Percentage Change in Lumbar Spine BMD (Bone Mineral Density) — 1.698; 1.440 Percent change
N/A N=131 Integrating U=U Into HIV Counseling in South Africa
HIV
Primary: Documented HIV Viral Load <200 Copies/mL at 3-10 Months — 22; 33 Participants
N/A N=19 The Impact of Circadian Misalignment on Colonic Barrier Homeostasis in Ulcerative Colitis
Ulcerative Colitis
Primary: Change in Dim Light Melatonin Onset (DLMO) From Baseline (Aligned) to Circadian Misalignment Misalignment — 20.72; 20.45; 23.05; 22.65 hours
Phase 2 N=15 Medications for Obstructive Sleep Apnea In Children With Down Syndrome
Obstructive Sleep Apnea · Down Syndrome
Primary: Obstructive Apnea-hypopnea Index (oAHI) — -3.79; -3.51 events per hour
N/A N=82 Adjunctive Family CBT for Veterans With Anxiety
Anxiety Disorder
Primary: Modified Treatment Evaluation Inventory — 32.13; 35.40; 34.29; 35.32 score on a scale